The U.S. government will pay Moderna $176 million to develop a mRNA vaccine to treat bird flu, as cases in dairy cows rise. Moderna's vaccine uses the same technology as COVID-19 vaccines and can be redirected if needed.
Key Points
Moderna awarded $176 million by U.S. government
Vaccine in early-stage testing
Can be redirected to target other forms of influenza
H5N1 virus detected in dairy cows, minimal risk to wider population
Pros
Accelerated development of pandemic influenza vaccine
Potential to treat bird flu in people
Utilizes mRNA technology for rapid development
Cons
Risk of redirecting project if new influenza threat emerges